On Monday, MaxCyte Inc (NASDAQ: MXCT) opened higher 11.59% from the last session, before settling in for the closing price of $4.40. Price fluctuations for MXCT have ranged from $3.16 to $5.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 18.61% annually for the last half of the decade. Company’s average yearly earnings per share was noted -11.32% at the time writing. With a float of $97.35 million, this company’s outstanding shares have now reached $105.30 million.
In an organization with 143 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 79.04%, operating margin of -101.56%, and the pretax margin is -78.36%.
MaxCyte Inc (MXCT) Insider Updates
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of MaxCyte Inc is 7.71%, while institutional ownership is 64.70%. The most recent insider transaction that took place on Dec 26 ’24, was worth 12,021. In this transaction Director of this company sold 3,000 shares at a rate of $4.01, taking the stock ownership to the 141,950 shares. Before that another transaction happened on Dec 26 ’24, when Company’s Affiliate proposed sale 12,000 for $4.11, making the entire transaction worth $49,320.
MaxCyte Inc (MXCT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -11.32% per share during the next fiscal year.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Check out the current performance indicators for MaxCyte Inc (MXCT). In the past quarter, the stock posted a quick ratio of 9.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.74 million. That was better than the volume of 0.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.70%. Additionally, its Average True Range was 0.29.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 97.21%, which indicates a significant increase from 94.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.81% in the past 14 days, which was higher than the 57.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.89, while its 200-day Moving Average is $4.11. However, in the short run, MaxCyte Inc’s stock first resistance to watch stands at $5.14. Second resistance stands at $5.36. The third major resistance level sits at $5.77. If the price goes on to break the first support level at $4.51, it is likely to go to the next support level at $4.10. Assuming the price breaks the second support level, the third support level stands at $3.88.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
There are currently 105,711K shares outstanding in the company with a market cap of 517.92 million. Presently, the company’s annual sales total 41,290 K according to its annual income of -37,920 K. Last quarter, the company’s sales amounted to 8,160 K and its income totaled -11,560 K.
